News | Hemodynamic Support Devices | January 16, 2018

Miracor Raises Funds for its Heart Attack Perfusion System

Funds will support clinical and prepare commercial activities for PiCSO Impulse System to improve perfusion during stenting for acute myocardial infarction patients

Miracor Medical Raises money for its PiCSO therapy used during stenting procedures in acute myocardial infarct (AMI) to intermittently increase pressure in the coronary venous system.

January 16, 2018 — Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) announced the closing of €25m as part of a Series D financing round. The new capital will be used to further develop and commercialize the PiCSO Impulse System. The round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor.

Participating in this financing round were the new Belgian and Walloon public investors SFPI, SRIW and Meusinvest, as well as the existing investors Earlybird Venture Capital, Delta Partners, SHS Gesellschaft für Beteiligungsmanagement, Biomed Invest and Peppermint Venture Partners. The financing includes equity and debt, as well as non-dilutive cash advance granted by Wallonia’s Government.

“Miracor Medical has shown that the PiCSO Impulse System may reduce infarct size and improve cardiac function. We are impressed with the company’s performance and the latest clinical data on the PiCSO Impulse System, which show statistically significant better results for PiCSO-treated patients in a propensity score matched control,” said Jack (Bing) Yang, managing partner at Ming Capital. “PiCSO has global potential and we look forward to supporting and partnering with Miracor Medical to improve the outcomes of patients following acute infarcts and bring the PiCSO Impulse System to the next stage of clinical development.”

Miracor Medical’s PiCSO therapy is provided during the stenting procedure of patients enduring acute myocardial infarct (AMI) and intermittently increases pressure in the coronary venous system, which leads to an improved microcirculatory flow and improved perfusion of the infarcted area. This leads to a smaller residual infarct size after AMI compared to non-PiCSO treated patients. New interim clinical data was also presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 annual meeting in early November in Denver. Decreased residual infarct size after AMI has shown to be directly correlated to reduced mortality and hospitalizations for heart failure.

To fulfill a condition of this financing, Miracor Austria has merged with Miracor Medical, and the company is relocating to Belgium to ensure the next phase of its growth and development.

For more information:


Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init